Our TRI CEO, Eric Zudak, shares his experience at EADV 2026 (including a mention of his extensive and expanding collection of travel chargers.) See the whole story HERE.
One takeaway from EADV was the continued and overwhelmingly enthusiastic response to LAMA: Thalocan’s patented Lesion Area Mapping Assistant, our cloud-based solution for enhancing lesion assessment in dermatologic clinical trials.
Investigators can securely capture clinical images, map lesions, and document severity assessments using their own device or a study-provided tablet.
LAMA enables real-time data sharing among investigators, CROs, and sponsors, with time-lapse review of treatment responses. Features include precise lesion mapping, standardized notations and numerous other tools to improve accuracy and data quality.
Many thanks to EADV 2026.
Learn more about LAMA at www.thalocan.com/lama